Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- FED Front & Center Again
- Roundtable Top Picks of the Week
- RTI: Sector Strength Charts - Where's the Opportunity Now?
- Surging Financial ETFs Beating the Market
- Utility Industry Stock Outlook - June 2013
- 3 Japanese Stocks to Buy Now
- Your Next Stock Should Be Making New Highs
- Anatomy of Success: Stoneridge (SRI)
- RTI: What Will the Fed Do Wednesday?
- AWS 6/19: Will Bernanke Clarify Matters Today?
- PFP 6/19: Investors Bold in Wake of the Fed
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 06/19/2013
| Company Name | Symbol | %Change |
|---|---|---|
| LUMOS NETWOR | LMOS | 4.96% |
| SONIC FOUNDR | SOFO | 4.40% |
| GREEN MOUNTA | GMCR | 3.58% |
| SUPPORTCOM I | SPRT | 3.97% |
| SHORETEL INC | SHOR | 3.22% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We recently reiterated a Neutral recommendation on The Medicines Company (MDCO - Analyst Report), which carries a Zacks #3 Rank (short-term Hold rating). The Medicines Company reported a first-quarter profit of 60 cents per share, well above the Zacks Consensus Estimate of 39 cents and the year-ago profit of 19 cents.
Performance was boosted by higher revenues. Revenues, up 9.8% at $112.1 million, surpassed the Zacks Consensus Estimate of $110 million.
The Medicines Company’s lead product, Angiomax (bivalirudin), is a specific and reversible direct thrombin inhibitor that was launched in early 2001. Despite the challenging economic scenario which has led to hospitals and patients cutting down on costly procedures, Angiomax sales in the first quarter of 2011 were up 9.7% year over year in the US.
The Medicines Company received a major boost in 2010 regarding its Angiomax patent extension case. The US Patent and Trademark Office (PTO) extended the principal patent on Angiomax by a year to August 2011 and has been instructed to treat the patent extension application as having been filed on a timely basis.
Moreover, the US Government decided against appealing the Court’s decision. These developments removed a significant overhang from the stock.
We are also pleased to see that management is actively pursuing in-licensing deals and acquisitions to drive growth. Deals include the acquisition of Germany-based Curacyte Discovery GmbH, the acquisition of Targanta Therapeutics and the acquisition of worldwide rights to MDCO-216 from Pfizer (PFE - Analyst Report).
Our biggest concern with The Medicines Company is the generic risk being faced by its lead product Angiomax. Several generic players like Teva (TEVA - Analyst Report), Hospira (HSP - Analyst Report), Mylan (MYL - Analyst Report), Dr. Reddy’s (RDY - Snapshot Report) and APP Pharma are all seeking approval for their generic versions of the product. Angiomax is The Medicines Company’s lead product, accounting for 99.8% of total revenues in 2010.
Get the full Analyst Report on MDCO - FREE
Get the full Snapshot Report on RDY - FREE
Get the full Analyst Report on HSP - FREE
Get the full Analyst Report on PFE - FREE
Get the full Analyst Report on TEVA - FREE
Get the full Analyst Report on MYL - FREE